Pfizer Corporation

Pfizer Products Inc.

Other

Ralph P Robinson

James P Rizzi

Ernest S Hamanaka

Peter Bertinato

Edward F Kleinman

Derek Lawrence Tickner

Marcus D Ewing

Michel A Couturier

Ellen Ruth Laird

Bradley Paul Morgan

Anthony Marfat

Wayne E Barth

Kelvin Cooper

Lawrence Alan Reiter

Todd A Blumenkopf

Kim F McClure

Kevin K Liu

Yves Andre Chantigny

Yves A Chantigny

A system for reversing heat transfer from an exhaust system assembly on a vehicle comprising an engine block assembly and transaxle assembly operatively connected and located in an engine compartment of an automobile. The system comprises a number one exhaust manifold stay mount, a number two exhaust manifold stay mount, and a front exhaust collector pipe bracket and stay mount. The system comprises an exhaust system with a front exhaust collector pipe located beneath the engine block assembly. The system comprises an engine block assembly heat shield with a cross-section generally comprising the shape of a 'U' that is located next to the surface of the engine block assembly. The engine block assembly heat shield is located over and overlays the front exhaust collector pipe bracket and stay mount, the number one exhaust manifold stay mount, and the number two exhaust manifold stay mount.

Internal combustion engine heat transfer system

The present invention provides compounds of the formula  and X, Y, n, R&#x2014;Rare as described in the specification which are modulators of the glucocorticoid receptor and are thus useful for the treatment of animals requiring glucocorticoid receptor agonist therapy. Glucocorticoid receptor modulators are useful in the treatment of certain inflammatory conditions.

Modulators of the glucocorticoid receptor

This invention relates to MTP/Apo-B secretion inhibitors of Formula (I) wherein R&#x2014;R, X, m and n are as defined in the specification, as well as pharmaceutical compositions comprising the compounds, and methods of use of the compounds and compositions. The compounds of the invention are useful in treating obesity and associated diseases, conditions or disorders.

Substituted quinoline compounds

This invention relates to MTP/Apo-B secretion inhibitors of Formula (I) wherein R-R, X, m and n are as defined in the specification, as well as pharmaceutical compositions comprising the compounds, and methods of use of the compounds and compositions. The compounds of the invention are useful in treating obesity and associated diseases, conditions or disorders.

Triamide-substituted heterobicyclic compounds

The present invention provides compounds of the formula wherein A is of the formula and X, Y, n, R&#x2013;Rare as described in the specification which are modulators of the glucocorticoid receptor and are thus useful for the treatment of animals requiring glucocorticoid receptor agonist therapy. Glucocorticoid receptor modulators are useful in the treatment of certain inflammatory conditions.

The present invention provides non-steroidal compounds of Formula I, including prodrugs and pharmaceutically acceptable salts thereof, which are selective modulators (e.g., agonists, partial agonists and antagonists) of a steroid receptor, specifically, the glucocorticoid receptor. The present invention also provides pharmaceutical compositions containing these compounds and methods for using these compounds to treat animals requiring glucocorticoid receptor agonist or antagonist therapy. Glucocorticoid receptor modulators are useful to treat diseases, such as obesity, diabetes, inflammation and others as described below. The present invention also provides processes for preparing these compounds

Glucocorticoid receptor modulators

2-oxo-imidazolidine-4-carboxylic acid hydroxamide compounds that inhibit matrix metalloproteinases

Arylsulfonylamino hydroxamic acid derivatives

The present invention relates to dioxocyclopentyl hydroxamide derivatives of the formula

Dioxocyclopentyl hydroxamic acids

A compound of the formula ##STR1## wherein n, X, R.sup.3, R.sup.4 and Ar are as defined above, useful in the treatment of a condition selected from the group consisting of arthritis, cancer, tissue ulceration, restenosis, periodontal disease, epidermolysis bullosa, scleritis and other diseases characterized by matrix metalloproteinase activity, AIDS, sepsis, septic shock and other diseases involving the production of TNF.

The present invention relates to a compound of the formula ##STR1## wherein R.sup.1, R.sup.2, R.sup.3 are as defined above, to pharmaceutical compositions and methods of treatment.

5-oxo-pyrrolidine-2-carboxylic acid hydroxamide derivatives

A compound of the formula ##STR1## wherein n, X, R.sup.3, R.sup.4 and Ar are as defined above, useful in the treatment of a condition selected from the group consisting of arthritis, cancer, tissue ulceration, restenosis, periodontal disease, epidermolysis bullosa, scleritis, bone resorption, loosening of artificial joint implants, atherosclerosis, multiple sclerosis, occular angiogenisis and other diseases characterized by matrix metalloproteinase activity, AIDS, sepsis, septic shock and other diseases involving the production of TNF.

Growing community of inventors

Gales Ferry, CT, United States of America

Ralph P Robinson